#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Colorectal adenocarcinoma Primary amyloidosis Oesophageal carcinoma Aplastic anaemia Non-small cell lung cancer recurrent Hereditary hypophosphataemic rickets Autoimmune demyelinating disease Fungal infection Renal cell carcinoma Bronchiectasis Orthostatic hypotension Familial hypertriglyceridaemia Congenital nephrogenic diabetes insipidus Metastatic gastric cancer Meningococcal immunisation More trials…

    Learn about Rare Diseases

    Combined immunodeficiency Antisynthetase syndrome – Life with Disease Erdheim-Chester disease – Diagnostics Waldenstrom’s macroglobulinaemia – Life with Disease Fabry’s disease – Trials in Disease Andersen-Tawil syndrome – Life with Disease Pemphigoid – Life with Disease Amyotrophic lateral sclerosis – Diagnostics Wolfram syndrome – Diagnostics Short-bowel syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tiotropium TRIACYLGLYCEROL LIPASE Tianeptine SOVATELTIDE AZD6234 Povetacicept Epinephrine Bitartrate Atazanavir Sorafenib Tosilate BUDOPRUTUG Belumosudil Mesilate Eteplirsen Daratumumab Mk-0482 Falbikitug Futibatinib Riboflavin Bp Alfacalcidol Levomethadone Hydrochloride Bms-986288 More therapies…

    Learn about Your Condition

    Vaginal cancer Thymoma malignant Venous thrombosis Somatic symptom disorder Myofascial pain syndrome Iron deficiency Malabsorption Insulin resistance Albuminuria Prostate cancer Chondrosarcoma metastatic Kidney transplant rejection Infertility Small cell carcinoma Endolymphatic hydrops More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Orszagos Onkologiai Intezet

Orszagos Onkologiai Intezet

Rath Gyorgy Utca 7-9, Kerulet, Budapest, 1122, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Adagrasib
    • Pembrolizumab
    Austria Belgium Bulgaria Croatia Czechia Denmark +13

  • Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    • HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
    • Bevacizumab
    • Carboplatin
    Czechia Finland France Germany Greece Hungary +6

  • Phase 3 Study of atebimetinib with gemcitabine and paclitaxel versus gemcitabine and paclitaxel in patients with metastatic pancreatic cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Pancreatic carcinoma metastatic
    Investigated Drugs:
    • Gemcitabine Hydrochloride
    • Paclitaxel
    Belgium Czechia France Germany Hungary Poland +2

  • Phase III Randomized Open‑Label Trial of BNT324 vs Docetaxel Plus Prednisone in Patients with Metastatic Castration‑Resistant Prostate Cancer

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    • Docetaxel
    • Prednisolone
    Belgium France Germany Hungary Italy Poland +1

  • Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Ly3484356
    • Anastrozole
    • Exemestane
    Austria Belgium Czechia Finland France Germany +10

  • Study on Everolimus and Exemestane for Patients with Metastatic Breast Cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • HER2 negative breast cancer
    • Hormone receptor positive breast cancer
    • Breast cancer
    Investigated Drugs:
    • Everolimus
    • Exemestane
    Hungary

  • Study on Datopotamab Deruxtecan and Rilvegostomig for Stage I Non-Small Cell Lung Cancer Patients with ctDNA-Positive or High-Risk Features

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage I
    Investigated Drugs:
    • Vinorelbine
    • Carboplatin
    • Cisplatin
    Belgium France Germany Hungary Italy The Netherlands +3

  • Study to Compare Zongertinib with Standard Treatment for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Pembrolizumab
    Austria Belgium France Germany Greece Hungary +7

  • Study on the Effectiveness and Safety of Luveltamab Tazevibulin Compared to Chemotherapy in Women with Relapsed Platinum-resistant Ovarian Cancer

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Stro-002
    • Doxorubicin Hydrochloride
    • Gemcitabine
    Austria Belgium Czechia Finland Germany Hungary +3

  • Study of Mirvetuximab Soravtansine and Bevacizumab for Maintenance in Adults with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    • Mirvetuximab Soravtansine
    • Prednisolone Acetate
    • Propylene Glycol
    Belgium Bulgaria Czechia France Germany Greece +5
Previous Page
1 … 5 6 7 8 9 … 17
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!